Republic of KoreaTuberculosis profile
Population  2016 51 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (2.4–2.7) 5.1 (4.8–5.3)
Mortality (HIV+TB only) 0.082 (0.033–0.15) 0.16 (0.07–0.3)
Incidence  (includes HIV+TB) 39 (36–42) 77 (71–82)
Incidence (HIV+TB only) 0.77 (0.44–1.2) 1.5 (0.86–2.3)
Incidence (MDR/RR-TB)** 2.4 (2.1–2.7) 4.8 (4.1–5.4)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.9 (1.8–2) 14 (13–15) 16 (15–17)
Males 2.1 (2–2.3) 21 (19–22) 23 (21–25)
Total 4 (3.8–4.3) 35 (32–37) 39 (36–42)
TB case notifications, 2016  
Total cases notified 39 245
Total new and relapse 36 435
          - % tested with rapid diagnostics at time of diagnosis 7%
          - % with known HIV status  
          - % pulmonary 81%
          - % bacteriologically confirmed among pulmonary 68%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 94% (87–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.07)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 600
(1 500–1 700)
Estimated % of TB cases with MDR/RR-TB 3.4% (3.1–3.7) 11% (9.4–12)  
% notified tested for rifampicin resistance 51% 55% 20 704
MDR/RR-TB cases tested for resistance to second-line drugs   645
Laboratory-confirmed cases MDR/RR-TB: 885, XDR-TB: 37
Patients started on treatment **** MDR/RR-TB: 913, XDR-TB: 37
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 84% 35 029
Previously treated cases, excluding relapse, registered in 2015 73% 3 375
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 63% 846
XDR-TB cases started on second-line treatment in 2014 59% 63
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
72% (53–100)
TB financing, 2017  
National TB budget (US$ millions) 54
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data